On November 27, 2023, Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 12,963,542 shares of common stock at a price of $21.36 per share and, in lieu of common stock, pre-funded warrants to purchase up to 3,422,380 shares of common stock at a price of $21.359 per pre-funded warrant, in a private placement. The aggregate gross proceeds from the offering are expected to be approximately $350 million, before deducting placement agent fees and offering expenses.

The WilmerHale team advising Arvinas in its private placement was led by Brian Johnson and Caroline Dotolo, and included Victoria Peluso, Michelle Sidle and Heidi Treiber.